Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
Recruiting
Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients in Gout (Pharm-UP) Study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * US Veterans with physician-diagnosed * Documented hyperuricemia (SU \> 6.8 milligrams per deciliter) * Satisfy American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) gout classification criteria * Report 1 or more flares in the prior 6 months * Receipt of a new urate-lowering therapy (ULT) prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria Exclusion Criteria: * Any patient intolerant or unable to take urate-lowering therapies (allopurinol or febuxostat) * Patients with a rheumatology encounter within the prior 3 months * Patients on an allopurinol dose \> 300 or a Febuxostat dose \> 40 * Patients with stage IV/V Chronic Kidney Disease (CKD) * Patients with a life expectancy \< 12 months * Patients with a concomitant medication of azathioprine or 6-MPC (urate-lowering therapy contraindicated)
About the study
This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.
What is being tested
- Pharmacist-Led (other)
Sponsor: VA Office of Research and Development · Participants: 310 · Started: Oct 1, 2026
Contact the study team
- Bridget Kramer · Phone: (402) 995-3206
Official record on ClinicalTrials.gov — NCT06887452
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.